Struggling Novavax struck a $1.4 billion deal with Sanofi on Friday to commercialize its existing COVID-19 vaccine and develop a combined jab to protect against both the coronavirus and influenza ...

1, said CEO John Jacobs. Earlier this month ... 2 strain for 2024-25 COVID-19 vaccines. Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based ...

It's the second straight year that rivals Moderna and Pfizer have gotten a head start in the race to roll out fall vaccines. Novavax Inc. is once again lagging behind rivals Pfizer Inc. and ...

The newly approved vaccine targets multiple circulating variants, promising enhanced protection and availability across ...

Novavax CEO Stanley Erck told CNN that filings have been delayed while the company puts together the manufacturing data that regulators require for approval. He told CNN: "The hard part of the ...

1, said CEO John Jacobs. JN.1 was the dominant strain ... 2 strain for 2024-25 COVID-19 vaccines. Novavax's traditional protein-based shot offers an alternative vaccine technology to those that ...

Novavax’s CEO said he believes boosters will be the company’s “biggest market” in the U.S. once it receives regulatory approval for its COVID-19 vaccine.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

1, said CEO John Jacobs. Earlier this month ... 2 strain for 2024-25 COVID-19 vaccines. Novavax’s traditional protein-based shot offers an alternative vaccine technology to those that are ...